These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 35240676)

  • 21. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
    Wang L; Møhlenberg M; Wang P; Zhou H
    Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
    Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
    Xiang T; Wang J; Zheng X
    Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
    Park YJ; Pinto D; Walls AC; Liu Z; De Marco A; Benigni F; Zatta F; Silacci-Fregni C; Bassi J; Sprouse KR; Addetia A; Bowen JE; Stewart C; Giurdanella M; Saliba C; Guarino B; Schmid MA; Franko NM; Logue JK; Dang HV; Hauser K; di Iulio J; Rivera W; Schnell G; Rajesh A; Zhou J; Farhat N; Kaiser H; Montiel-Ruiz M; Noack J; Lempp FA; Janer J; Abdelnabi R; Maes P; Ferrari P; Ceschi A; Giannini O; de Melo GD; Kergoat L; Bourhy H; Neyts J; Soriaga L; Purcell LA; Snell G; Whelan SPJ; Lanzavecchia A; Virgin HW; Piccoli L; Chu HY; Pizzuto MS; Corti D; Veesler D
    Science; 2022 Nov; 378(6620):619-627. PubMed ID: 36264829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 Omicron and its current known unknowns: A narrative review.
    Le TTB; Vasanthakumaran T; Thi Hien HN; Hung IC; Luu MN; Khan ZA; An NT; Tran VP; Lee WJ; Abdul Aziz JM; Ali T; Dumre SP; Huy NT
    Rev Med Virol; 2023 Jan; 33(1):e2398. PubMed ID: 36150052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
    Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
    Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.
    Tada T; Zhou H; Dcosta BM; Samanovic MI; Chivukula V; Herati RS; Hubbard SR; Mulligan MJ; Landau NR
    EBioMedicine; 2022 Apr; 78():103944. PubMed ID: 35465948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
    Xia S; Wang L; Zhu Y; Lu L; Jiang S
    Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.
    Ai J; Wang X; He X; Zhao X; Zhang Y; Jiang Y; Li M; Cui Y; Chen Y; Qiao R; Li L; Yang L; Li Y; Hu Z; Zhang W; Wang P
    Cell Host Microbe; 2022 Aug; 30(8):1077-1083.e4. PubMed ID: 35594867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Bowen JE; Rosen LE; Saliba C; Zepeda SK; Culap K; Pinto D; VanBlargan LA; De Marco A; di Iulio J; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà PE; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Snell G; Veesler D; Corti D
    Nature; 2022 Feb; 602(7898):664-670. PubMed ID: 35016195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.
    Chen Z; Zhang P; Matsuoka Y; Tsybovsky Y; West K; Santos C; Boyd LF; Nguyen H; Pomerenke A; Stephens T; Olia AS; Zhang B; De Giorgi V; Holbrook MR; Gross R; Postnikova E; Garza NL; Johnson RF; Margulies DH; Kwong PD; Alter HJ; Buchholz UJ; Lusso P; Farci P
    Cell Rep; 2022 Nov; 41(5):111528. PubMed ID: 36302375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
    J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Zhu Y; Hu Y; Liu N; Chong H; He Y
    Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
    Evans JP; Zeng C; Qu P; Faraone J; Zheng YM; Carlin C; Bednash JS; Zhou T; Lozanski G; Mallampalli R; Saif LJ; Oltz EM; Mohler PJ; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2022 Aug; 30(8):1093-1102.e3. PubMed ID: 35526534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.